Member Info for crumbs

Hmm Ruck obviously no guarantees on anything yet but with target market's worth hundreds of billions a year I think you don't have to undervalue the potential of unrivalled data.......no one ever said 8 quid out of the blue it only comes with data deals and products in use.....I expect to know does covidty have a market and does Modi 1 work within 2 years

Ruck, I'd like to think we will have the kind of data and reaction to it within 2 years that could indeed mean £8 or 00000.8p a share ....obviously not within 2 months time though lol.... Covidity data first then modi1 hopefully some SCIB1 combo... and new trials initiated all happening in the coming year

'Our differing views are exactly what makes a market!' now on that we are in total agreement oh and a shared interest in scancell both sp wise and activity-wise :) although maybe one of us is more concerned about current sp than the other is... again for me it is a longer game I am here to find out is Lindy right or wrong Redmile/Vulpes have by funding given Lindy that opportunity ....

Still lost me!! lol so what you are saying is the indications are no positive data is coming due to CLN extension?
Also the Diggle wiggles had a lot to do with keeping sp above 20p as well as keeping it below 30p too... market does what it does it is most sentiment driven till told otherwise ie suddenly Merck move in on Covidity then market goes oh that is good innit I'm not waiting on that moment to me at sub 20p I see it as a buy for me personally others will have their own values but scancell has a lot of long and strong holders and I do not see that changing especially now years of building IP is actually coming to fruit... by this time next year I'd expect Lindy will be shown to be either right or wrong .....

And all that...
Pfizer and Moderna forecast $90 billion of sales of their mRNA vaxs for 2022
https://www.ft.com/content/e7865240-88cc-41ba-86c2-3a020d1431f9

' We have recently initiated our COVIDITY programme, which aims to develop a next generation, DNA-based COVID-19 vaccine, which we believe may have advantages over current mRNA-based vaccines, and we look forward to reporting safety and immunogenicity data during H1 2022'

Of course, we are but one in the race and will need a big backer not to mention the supporting data but that 'advantages over current mRNA' ...... It will not go unnoticed if that data does indeed back it of that I'm sure!

AB I'd be surprised if your post is removed !
My main misunderstanding was your idea of a less buoyant sp is somehow better for attracting funds when funds will surely come from an interest in the products and the credibility of the company not the sp....
The sp can do anything can be 10% today 20$ up tomorrow.... yes we have had a long period of maintain above 20p is that broken now? ... but early to say isn't it and like I said to me it is not an issue sub 20p it becomes a buy to me as I am indeed looking for the big rewards not just though also the 10%s :)

Not sure I get what you are meaning there AB ? I should expect any coming funds to come from either deal/s of which there could be multiple considering the pipeline or the likes of CEPI/Gov and in both case the sp will be irrelevant ... although the effect of either and or both would be IMHO very sp positive.... just a bit of patience for data required.... there looks to be plenty of newsflow coming ... anyways if we drift down it won't concern me too much with all that supporting moolah in the bank and it is being spent wisely on IP building plus the continued extended support of RM...

I've taken a little bite.... Diggle does like his sub 20p wiggle.... we'll see

Yes I think they do but it may well be the most valuable thing they have if electroporation is on its way out :)

It would be expensive to pour the current SCIB1 batch down the loo... also they are still actively recruiting and could by a miracle actually dose a patient on that trial anytime so I wonder is it a case of a new trial of SCIB1 + with a much paired down to the bone SCIb1 + Ichor combo trial.... dunno but be interesting to find out... it is possible there is already some interest in the new look ImmunoBody platform

Yeah, that is one of the most interesting reveals of the RNS....
On that with the Covidity trial now running and gaining data surely if that comes good and the pharmajet proves to be an effective replacement for the Ichor the commercial potential and attractiveness of the next-gen SCIB/Avidimabs must surely increase hugely....

Lindy gets the chance to prove if her techs are 'unrivalled' or not...... plenty could happen from now on in beginning with Covidity data

Looking like they must be happy with the pharmajet too as sounds like that potentially could replace the ichor in SCIB1 trial.... loads going on and I expect plenty of newsflow too

Investable is the term lol ...... which was a bit more tricky with one £3million in the bank and no active trials ...thankfully those days are behind us.... again the potential amount of coming trials is fantastic for the potential here....

Well we all know they will burn through the £40 million that is its purpose after all ... just they have not burnt through it all in a year lol so plenty left for what could be coming very interesting trials in SCIB1+ SCIB2+ Glycan MaBs including AvidiMab and modi2 ..... one hell of a lot of data when including current Covidity modi1 and original SCIB1 trials....

The cashburn does not look too bad to me considering how much has been achieved with what has been so far spent...
of note :

'Given the significant improvements in potency, utility and patent life with iSCIB1+, the Company is currently evaluating its strategic options for the current SCIB1 programme which could include changes to the product, protocol and delivery system and will update the market in H1 2022 with regards to its strategy.'

Also Zacari gets mentioned and does indeed look like part of a glycan MaB strategy

modi2 getting manufactured next year.... potential of many trials indeed!

Happy with it all

I think the name change will have a positive impact too

That's what I wanted to hear, happy with that and will build my position

That's what I wanted ??....happy with that and will build my position here

Must say I like the new name and agree with your post rush just think it could have been all managed a bit better as clearly there has not been recent value-added to the company when there ought to have still for longer-term this should all play out well and probably the gold co will list some place again agree anywhere but AIM, please!